» Articles » PMID: 37533469

A Study on the Correlations Between Acoustic Speech Variables and Bradykinesia in Advanced Parkinson's Disease

Overview
Journal Front Neurol
Specialty Neurology
Date 2023 Aug 3
PMID 37533469
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Very few studies have assessed the presence of a possible correlation between speech variables and limb bradykinesia in patients with Parkinson's disease (PD). The objective of this study was to find correlations between different speech variables and upper extremity bradykinesia under different medication conditions in advanced PD patients.

Methods: Retrospective data were collected from a cohort of advanced PD patients before and after an acute levodopa challenge. Each patient was assessed with a perceptual-acoustic analysis of speech, which included several quantitative parameters [i.e., maximum phonation time (MPT) and intensity (dB)]; the Unified Parkinson's Disease Rating Scale (UPDRS) (total scores, subscores, and items); and a timed test (a tapping test for 20 s) to quantify upper extremity bradykinesia. Pearson's correlation coefficient was applied to find correlations between the different speech variables and the tapping rate.

Results: A total of 53 PD patients [men: 34; disease duration: 10.66 (SD 4.37) years; age at PD onset: 49.81 years (SD 6.12)] were included. Levodopa intake increased the MPT of sustained phonation ( < 0.01), but it reduced the speech rate ( = 0.05). In the defined-OFF condition, MPT of sustained phonation positively correlated with both bilateral mean ( = 0.044, -value:0.299) and left ( = 0.033, -value:0.314) tapping. In the defined-ON condition, the MPT correlated positively with bilateral mean tapping ( = 0.003), left tapping ( = 0.003), and right tapping ( = 0.008).

Conclusion: This study confirms the presence of correlations between speech acoustic variables and upper extremity bradykinesia in advanced PD patients. These findings suggest common pathophysiological mechanisms.

Citing Articles

Speech profile in different clinical PSP phenotypes: an acoustic-perceptual study.

Di Rauso G, Cavallieri F, Gessani A, Fontanesi D, Coniglio S, Fioravanti V Neurol Sci. 2024; 46(2):769-774.

PMID: 39453558 DOI: 10.1007/s10072-024-07833-w.


Speech, Gait, and Vestibular Function in Cerebellar Ataxia with Neuropathy and Vestibular Areflexia Syndrome.

Di Rauso G, Castellucci A, Cavallieri F, Tozzi A, Fioravanti V, Monfrini E Brain Sci. 2023; 13(10).

PMID: 37891834 PMC: 10605709. DOI: 10.3390/brainsci13101467.


Long-term effects of subthalamic nucleus deep brain stimulation on speech in Parkinson's disease.

Gessani A, Cavallieri F, Fioravanti V, Campanini I, Merlo A, Di Rauso G Sci Rep. 2023; 13(1):11462.

PMID: 37454168 PMC: 10349811. DOI: 10.1038/s41598-023-38555-2.

References
1.
Cavallieri F, Budriesi C, Gessani A, Contardi S, Fioravanti V, Menozzi E . Dopaminergic Treatment Effects on Dysarthric Speech: Acoustic Analysis in a Cohort of Patients With Advanced Parkinson's Disease. Front Neurol. 2021; 11:616062. PMC: 7892955. DOI: 10.3389/fneur.2020.616062. View

2.
Skodda S, Flasskamp A, Schlegel U . Instability of syllable repetition as a model for impaired motor processing: is Parkinson's disease a "rhythm disorder"?. J Neural Transm (Vienna). 2010; 117(5):605-12. DOI: 10.1007/s00702-010-0390-y. View

3.
Jost S, Kaldenbach M, Antonini A, Martinez-Martin P, Timmermann L, Odin P . Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals. Mov Disord. 2023; 38(7):1236-1252. DOI: 10.1002/mds.29410. View

4.
Magrinelli F, Picelli A, Tocco P, Federico A, Roncari L, Smania N . Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation. Parkinsons Dis. 2016; 2016:9832839. PMC: 4913065. DOI: 10.1155/2016/9832839. View

5.
Lechien J, Blecic S, Huet K, Delvaux V, Piccaluga M, Roland V . Voice quality outcomes of idiopathic Parkinson's disease medical treatment: A systematic review. Clin Otolaryngol. 2018; 43(3):882-903. DOI: 10.1111/coa.13082. View